Translation and Clinical Development of Antithrombotic Aptamers.

about

Multivalent Aptamers: Versatile Tools for Diagnostic and Therapeutic Applications The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36.

P2860

Q28073119-CA7B033F-6837-421B-88B3-40FDC41405DB Q47222078-562C38DF-B188-4986-8042-439EC78183BF

P2860

Translation and Clinical Development of Antithrombotic Aptamers.

Item

http://www.wikidata.org/entity/Q36987361

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Translation and Clinical Development of Antithrombotic Aptamers.

@en

type

Item

label

Translation and Clinical Development of Antithrombotic Aptamers.

@en

prefLabel

Translation and Clinical Development of Antithrombotic Aptamers.

@en

P1476

Translation and Clinical Development of Antithrombotic Aptamers.

@en

P2093

Bruce A Sullenger

http://www.w3.org/2001/XMLSchema#string

Richard C Becker

http://www.w3.org/2001/XMLSchema#string

Shahid M Nimjee

http://www.w3.org/2001/XMLSchema#string

Thomas J Povsic

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PEG immunity: emergence, characteristics, and unaddressed questions.

A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

Generation of species cross-reactive aptamers using "toggle" SELEX.

Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.

RNA aptamers as reversible antagonists of coagulation factor IXa.

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass.

P304

147-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/NAT.2015.0581

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294920589

http://www.w3.org/2001/XMLSchema#string

P698

26882082

http://www.w3.org/2001/XMLSchema#string

P932

4900189

http://www.w3.org/2001/XMLSchema#string

Translation and Clinical Development of Antithrombotic Aptamers.

about

P2860

P2860

Translation and Clinical Development of Antithrombotic Aptamers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932